What the FDA labels say about taking them together
Paroxetine and selegiline
Paroxetine's FDA label of February 12, 2026 names selegiline in its drug interactions section, and selegiline's label names paroxetine too. The selegiline label: “EMSAM is contraindicated with selective serotonin reuptake inhibitors; serotonin and norepinephrine reuptake inhibitors; the tricyclic antidepressants clomipramine and imipramine, the opiate analgesics meperidine …”
Check it at the source: the paroxetine FDA label on DailyMed (effective February 12, 2026, Mylan Pharmaceuticals Inc.); the selegiline FDA label on DailyMed (effective August 7, 2024, Rising Pharma Holdings, Inc.).
What does the paroxetine label say about selegiline?
Paroxetine label, drug interactionsExamples; selegiline, tranylcypromine, isocarboxazid, phenelzine, linezolid, methylene blue
Source: FDA drug label (Paroxetine), Mylan Pharmaceuticals Inc., effective February 12, 2026 (SPL set 89dd7e24-85fc-4152-89ea-47ec2b48a1ed), via openFDA; the full label on DailyMed
What does the selegiline label say about paroxetine?
Selegiline label, warningsSimilar signs have been reported in some patients on the combination of selegiline (10 mg a day) and selective serotonin reuptake inhibitors including fluoxetine, sertraline and paroxetine.
Emsam label (Viatris Specialty LLC, May 15, 2020), contraindicationsEMSAM (selegiline transdermal system) is contraindicated with selective serotonin reuptake inhibitors (SSRIs, e.g., fluoxetine, sertraline, and paroxetine); serotonin and norepinephrine reuptake inhibitors (SNRIs, e.g., venlafaxine and duloxetine); the tricyclic antidepressants clomipramine and imipramine, the opiate analgesics meperidine, tramadol, methadone, pentazocine, and propoxyphene; and the antitussive agent dextromethorphan because of a risk of serotonin syndrome when EMSAM is used with these agents [see Warnings and Precautions (5.2) and Drug Interactions (7.1) ].
Source: FDA drug label (Emsam, NDA021336), Viatris Specialty LLC, effective May 15, 2020 (SPL set b891bd9f-fdb8-4862-89c5-ecdd700398a3), via openFDA
Source: FDA drug label (Selegiline Hydrochloride), Rising Pharma Holdings, Inc., effective August 7, 2024 (SPL set 23c4481f-d150-40c6-addb-b3e454ca914f), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Paroxetine | Selegiline | |
|---|---|---|
| Labeled for | Depression, Anxiety, Menopause symptoms | Parkinson's disease, Depression |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.0611 per tablet 20 mg tablet | $0.756 per capsule 5 mg capsule |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once